88 related articles for article (PubMed ID: 17481779)
21. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
22. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.
Laburthe M; Couvineau A; Tan V
Peptides; 2007 Sep; 28(9):1631-9. PubMed ID: 17574305
[TBL] [Abstract][Full Text] [Related]
23. Role of CREB in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells.
Guan CX; Cui YR; Sun GY; Yu F; Tang CY; Li YC; Liu HJ; Fang X
Regul Pept; 2009 Feb; 153(1-3):64-9. PubMed ID: 19136032
[TBL] [Abstract][Full Text] [Related]
24. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
25. New nonradioactive technique for vasoactive intestinal peptide-receptor-ligand-binding studies.
Haberl I; Habringer DS; Andreae F; Artl A; Mosgoeller W
Ann N Y Acad Sci; 2006 Jul; 1070():313-6. PubMed ID: 16888184
[TBL] [Abstract][Full Text] [Related]
26. Differential binding of calmodulin domains to constitutive and inducible nitric oxide synthase enzymes.
Spratt DE; Taiakina V; Palmer M; Guillemette JG
Biochemistry; 2007 Jul; 46(28):8288-300. PubMed ID: 17580957
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro.
Lee H; Park K; Kim JS; Lee SJ
J Neurosci Res; 2009 Jan; 87(1):171-8. PubMed ID: 18683246
[TBL] [Abstract][Full Text] [Related]
30. A thermodynamic study of ligand binding to the first three domains of the human insulin receptor: relationship between the receptor alpha-chain C-terminal peptide and the site 1 insulin mimetic peptides.
Menting JG; Ward CW; Margetts MB; Lawrence MC
Biochemistry; 2009 Jun; 48(23):5492-500. PubMed ID: 19459609
[TBL] [Abstract][Full Text] [Related]
31. Effective mast cell degranulating peptide inhibitors of the IgE/Fc epsilonRI receptor interaction.
Buku A; Keselman I; Lupyan D; Mezei M; Price JA
Chem Biol Drug Des; 2008 Aug; 72(2):133-9. PubMed ID: 18624811
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors.
Langer I; Robberecht P
Biochem Soc Trans; 2007 Aug; 35(Pt 4):724-8. PubMed ID: 17635134
[TBL] [Abstract][Full Text] [Related]
33. Production, analysis and bioactivity of recombinant vasoactive intestinal peptide analogs.
Raingeaud J; Lavergne F; Lelievre V; Muller JM; Julien R; Cenatiempo Y
Biochimie; 1996; 78(1):14-25. PubMed ID: 8725006
[TBL] [Abstract][Full Text] [Related]
34. Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
de Maria S; Metafora V; Metafora S; Ravagnan G; Cartení M; Pontoni G; Facchiano A; Lepretti M; Severino B; Caliendo G; Santagada V; Langer I; Robberecht P
J Pept Sci; 2008 Jan; 14(1):102-9. PubMed ID: 17883247
[TBL] [Abstract][Full Text] [Related]
35. Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.
Pan CQ; Hamren S; Roczniak S; Tom I; DeRome M
Peptides; 2008 Mar; 29(3):479-86. PubMed ID: 17942192
[TBL] [Abstract][Full Text] [Related]
36. The vasoactive intestinal peptide receptor turnover in pulmonary arteries indicates an important role for VIP in the rat lung circulation.
Petkov V; Gentscheva T; Schamberger C; Haberl I; Artl A; Andreae F; Mosgoeller W
Ann N Y Acad Sci; 2006 Jul; 1070():481-3. PubMed ID: 16888213
[TBL] [Abstract][Full Text] [Related]
37. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
Matthiesen K; Nielsen J
Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
[TBL] [Abstract][Full Text] [Related]
38. Characterization of peptide 20-30 of follicle stimulating hormone receptor as an antagonist of receptor activity: significance of charged residues.
Dupakuntla M; Ghosalkar JD; Mahale SD
Chem Biol Drug Des; 2009 Jan; 73(1):108-14. PubMed ID: 19152639
[TBL] [Abstract][Full Text] [Related]
39. Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region.
Fujisawa D; Yamazaki Y; Lomonte B; Morita T
Biochem J; 2008 May; 411(3):515-22. PubMed ID: 18251716
[TBL] [Abstract][Full Text] [Related]
40. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
Stone SR; Giragossian C; Mierke DF; Jackson GE
Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
